About Genmab
Genmab is a company based in Copenhagen (Denmark) founded in 1999 by Jan van de Winkel.. The company has 2,680 employees as of December 31, 2024. Genmab has completed 2 acquisitions, including Merus and Profound Bio. Genmab operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Copenhagen, Denmark
- Employees 2680 as on 31 Dec, 2024
- Founders Jan van de Winkel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genmab A/S
-
Annual Revenue
$3 B (USD)30.67as on Dec 31, 2024
-
Net Profit
$1.09 B (USD)80.24as on Dec 31, 2024
-
EBITDA
$1.03 B (USD)31.3as on Dec 31, 2024
-
Latest Funding Round
$181.27 M (USD), Post-IPO
Jan 23, 2014
- Investors
-
Employee Count
2680
as on Dec 31, 2024
-
Investments & Acquisitions
Merus
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genmab
Genmab is a publicly listed company on the OMXCOP with ticker symbol GMAB in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
79 people
Software Development Team
53 people
Human Resources and Administration
27 people
Finance and Accounting
25 people
Product Management Team
20 people
Operations Team
15 people
Senior Team
14 people
Legal and Compliance
13 people
Unlock access to complete
Funding Insights of Genmab
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $181.3M
-
First Round
First Round
(01 Oct 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2014 | Amount | Post-IPO - Genmab | Valuation |
investors |
|
| Jul, 2010 | Amount | Post-IPO - Genmab | Valuation |
investors |
|
| Oct, 2009 | Amount | Post-IPO - Genmab | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genmab
Genmab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GSK. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genmab
Genmab has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Merus and Profound Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel cancer therapies are developed via antibody-drug conjugates.
|
2018 | ||||
|
Antibody-based drugs for cancer treatment are developed using bispecific engineering.
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Genmab
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genmab Comparisons
Competitors of Genmab
Genmab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genmab
Frequently Asked Questions about Genmab
When was Genmab founded?
Genmab was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Where is Genmab located?
Genmab is headquartered in Copenhagen, Denmark.
Who is the current CEO of Genmab?
Jan van de Winkel is the current CEO of Genmab. They have also founded this company.
How many employees does Genmab have?
As of Dec 31, 2024, the latest employee count at Genmab is 2,680.
What is the annual revenue of Genmab?
Annual revenue of Genmab is $3B as on Dec 31, 2024.
What does Genmab do?
Genmab was established in 1999 in Copenhagen, Denmark, within the biotechnology sector. Antibody-based treatments for cancer and autoimmune conditions are created using proprietary platforms such as DuoBody, HexaBody, DuoHexaBody, and HexElect. A product pipeline is maintained, featuring items like Teprotumumab for thyroid eye disease, Tisotumab vedotin for certain solid tumors and cervical cancer, and Darzalex for multiple myeloma, with operations centered on research and development.
Who are the top competitors of Genmab?
Genmab's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Is Genmab publicly traded?
Yes, Genmab is publicly traded on OMXCOP under the ticker symbol GMAB.
How many acquisitions has Genmab made?
Genmab has made 2 acquisitions, including Merus, and Profound Bio.
Who are Genmab's investors?
Genmab has 1 investor. Key investors include GSK.
What is Genmab's ticker symbol?
The ticker symbol of Genmab is GMAB on OMXCOP.